Why Bluebird’s Downgrade Sent These Two Rivals Skyrocketing – Investor’s Business Daily
Investor’s Business Daily |
Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing
Investor’s Business Daily Crispr rallied 4.6%, near 18.70, as Editas popped 3.7%, near 24.90, on Bluebird's downgrade. All three are working on therapies to treat sickle cell disease, a group of inherited blood disorders. Therapies from Crispr and Editas are showing promise … |
